MedTrace Logo

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

NCT02182778 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2019-02-21

No results posted yet for this study

Summary

To validate the superiority of Gemcitabine/Cisplatin/S-1 over Gemcitabine/Cisplatin for unresectable biliary tract cancer.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

Gemcitabine/Cisplatin

Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.

DRUG

Gemcitabine/Cisplatin /S-1

S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.

Sponsors & Collaborators

  • Kansai Hepatobiliary Oncology Group

    lead NETWORK

Principal Investigators

  • Masashi Kanai · Kyoto University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-09
Primary Completion
2016-02-04
Completion
2018-04-16

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02182778 on ClinicalTrials.gov